Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | PREP | P48147 | 5/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28367 | 1.00 | L3MBTL1 (0.67) | L3MBTL1NPC1RAB9APREPTSHR | |
| SCHEMBL16750358 | 0.83 | PREP (0.58) | L3MBTL1PREPTSHRALDH1A1CTRB1 | |
| SCHEMBL9371882 | 0.82 | PREP (0.62) | L3MBTL1PREPTSHRCTRB1NPSR1 | |
| SCHEMBL11262909 | 0.81 | PREP (0.69) | L3MBTL1PREPTSHRCTRB1NPSR1 | |
| SCHEMBL11262912 | 0.81 | PREP (0.69) | L3MBTL1PREPTSHRCTRB1NPSR1 | |
| SCHEMBL30659283 | 0.81 | NPC1 (1.00) | L3MBTL1NPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL7469639 | 0.81 | NPC1 (1.00) | L3MBTL1NPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL8750854 | 0.80 | PREP (0.68) | L3MBTL1PREPTSHRCTRB1NPSR1 | |
| SCHEMBL488744 | 0.80 | PREP (0.68) | L3MBTL1PREPTSHRCTRB1NPSR1 | |
| SCHEMBL20678314 | 0.80 | PREP (0.71) | L3MBTL1PREPTSHRALDH1A1CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | HDAC1, HDAC11, HDAC3 | L3MBTL1 1337/4885NPC1 684/4885RAB9A 2819/4885 |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | L3MBTL1 1354/4885NPC1 650/4885RAB9A 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.